Kensington Investment Counsel, LLC Concert Pharmaceuticals, Inc. Transaction History

Kensington Investment Counsel, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 15, 2023	SELL	$4.34 - $5.84 $78,996 - $106,299	-18,202 Reduced 23.7%	58,599 $342,000
Q3 2022 Nov 14, 2022	BUY	$4.27 - $7.2 $1,908 - $3,218	447 Added 0.59%	76,801 $515,000
Q2 2022 Jul 15, 2022	SELL	$2.8 - $6.36 $1,106 - $2,512	-395 Reduced 0.51%	76,354 $321,000
Q1 2022 May 16, 2022	BUY	$2.73 - $3.94 $209,524 - $302,391	76,749 New	76,749 $259,000
Q1 2022 May 13, 2022	SELL	$2.73 - $3.94 $233,368 - $336,803	-85,483 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$2.69 - $4.22 $2,999 - $4,705	1,115 Added 1.32%	85,483 $269,000
Q2 2021 Aug 13, 2021	BUY	$3.77 - $5.24 $7,411 - $10,301	1,966 Added 2.39%	84,368 $356,000
Q1 2021 May 13, 2021	BUY	$4.86 - $13.07 $33,383 - $89,777	6,869 Added 9.09%	82,402 $411,000
Q4 2020 Feb 16, 2021	BUY	$9.48 - $12.84 $716,052 - $969,843	75,533 New	75,533 $955,000

Ticker CNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,934,600
Description
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has s...

Get notified when there are updates to the investment portfolio of Kensington Investment Counsel, LLC, based on Form 13F filings with the SEC.

Stay updated on Kensington Investment Counsel, LLC with notifications on news.